This is a working overview of batch purity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
=== Other pursuits === In November 2023, the first issue of Holy Roller, a comic written by Samberg, Rick Remender, Joe Trohman and illustrated by Roland Boschi, was released and published by Image Comics. It is about a pro bowler who is forced to quit his dream job and return to his hometown, which he soon discovers has been overrun by Neo-Nazis, leading him to become a trick bowling ball-wielding Jewish superhero. Samberg co-hosts The Lonely Island and Seth Meyers Podcast alongside Schaffer, Taccone and Seth Meyers, which discusses the Lonely Island's SNL Digital Shorts.
== Further reading == Abelshauser, Werner; von Hippel, Wolfgang; Johnson, Jeffrey Allan; Stokes, Raymond G. (2003). German Industry and Global Enterprise. BASF: The History of a Company. New York: Cambridge University Press. ISBN 978-0-521-82726-3. Beer, John J. The Emergence of the German Dye Industry (1959).
2.A.1 Major Facilitator superfamily (MFS), see also Lactose permease, Phosphate permease and Glucose transporter 2.A.2 The Glycoside-Pentoside-Hexuronide (GPH):Cation Symporter Family 2.A.3 The Amino Acid-Polyamine-Organocation (APC) Family 2.A.4 Cation diffusion facilitator (CDF) Family 2.A.5 Zinc (Zn2+)-Iron (Fe2+) Permease Family 2.A.6 Resistance-Nodulation-Cell Division Superfamily, see also SecDF protein-export membrane protein 2.A.7 The Drug/Metabolite Transporter (DMT) Superfamily 2.A.8 The Gluconate:H+ Symporter (GntP) Family 2.A.9 The Membrane Protein Insertase (YidC/Alb3/Oxa1) Family 2.A.10 The 2-Keto-3-Deoxygluconate Transporter (KdgT) Family 2.A.11 The Citrate-Mg2+:H+ (CitM) Citrate-Ca2+:H+ (CitH) Symporter (CitMHS) Family 2.A.12 ATP:ADP Antiporter Family 2.A.13 The C4-Dicarboxylate Uptake (Dcu) Family 2.A.14 Lactate Permease Family 2.A.15 The Betaine/Carnitine/Choline Transporter (BCCT) Family 2.A.16 Tellurite-resistance/Dicarboxylate Transporter Family 2.A.17 Proton-dependent Oligopeptide Transporter Family 2.A.18 The Amino Acid/Auxin Permease (AAAP) Family 2.A.19 The Ca2+:Cation Antiporter (CaCA) Family 2.A.20 The Inorganic Phosphate Transporter (PiT) Family 2.A.21 Solute:Sodium Symporter Family 2.A.22 The Neurotransmitter:Sodium Symporter Family 2.A.23 The Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) Family 2.A.24 The 2-Hydroxycarboxylate Transporter (2-HCT) Family 2.A.25 Alanine or Glycine:Cation Symporter (AGCS) Family 2.A.26 The Branched Chain Amino Acid:Cation Symporter (LIVCS) Family 2.A.27 The Glutamate:Na+ Symporter (ESS) Family 2.A.28 Bile Acid:Na+ Symporter Family 2.A.29 Mitochondrial carrier Family 2.A.30 Cation-Chloride Cotransporter (CCC) Family 2.A.31 Anion Exchanger Family 2.A.32 The Silicon Transporter (Sit) Family 2.A.33 NhaA Na+:H+ Antiporter (NhaA) Family 2.A.34 The NhaB Na+:H+ Antiporter (NhaB) Family 2.A.35 The NhaC Na+:H+ Antiporter (NhaC) Family 2.A.36 Monovalent Cation:Proton Antiporter-1 (CPA1) Family 2.A.37 Monovalent Cation:Proton Antiporter-2 (CPA2) Family 2.A.38 K+ Transporter (Trk) Family 2.A.39 Nucleobase:Cation Symporter-1 (NCS1) Family 2.A.40 Nucleobase:Cation Symporter-2 (NCS2) Family 2.A.41 The Concentrative Nucleoside Transporter (CNT) Family 2.A.42 The Hydroxy/Aromatic Amino Acid Permease (HAAAP) Family 2.A.43 The Lysosomal Cystine Transporter (LCT) Family 2.A.45 Arsenite-Antimonite Efflux Family 2.A.46 The Benzoate:H+ Symporter (BenE) Family 2.A.47 Divalent Anion:Na+ Symporter (DASS) Family 2.A.48 The Reduced Folate Carrier (RFC) Family 2.A.49 Chloride Carrier/Channel (ClC) Family 2.A.50 The Glycerol Uptake (GUP) Family 2.A.51 The Chromate Ion Transporter (CHR) Family 2.A.52 The Ni2+-Co2+ Transporter (NiCoT) Family 2.A.53 Sulfate permease (SulP) Family 2.A.54 The Mitochondrial Tricarboxylate Carrier (MTC) Family 2.A.55 The Metal Ion (Mn2+-iron) Transporter (Nramp) Family 2.A.56 The Tripartite ATP-independent Periplasmic Transporter (TRAP-T) Family 2.A.57 The Equilibrative Nucleoside Transporter (ENT) Family 2.A.58 The Phosphate:Na+ Symporter (PNaS) Family 2.A.59 The Arsenical Resistance-3 (ACR3) Family 2.A.60 Organo Anion Transporter (OAT) Family 2.A.61 The C4-dicarboxylate Uptake C (DcuC) Family 2.A.62 The NhaD Na+:H+ Antiporter (NhaD) Family 2.A.63 The Monovalent Cation (K+ or Na+):Proton Antiporter-3 (CPA3) Family 2.A.64 Twin Arginine Targeting (Tat) Family 2.A.65 The Bilirubin Transporter (BRT) Family 2.A.66 The Multidrug/Oligosaccharidyl-lipid/Polysaccharide (MOP) Flippase Superfamily 2.A.67 The Oligopeptide Transporter (OPT) Family 2.A.68 The p-Aminobenzoyl-glutamate Transporter (AbgT) Family 2.A.69 The Auxin Efflux Carrier (AEC) Family 2.A.70 The Malonate:Na+ Symporter (MSS) Family 2.A.71 The Folate-Biopterin Transporter (FBT) Family 2.A.72 The K+ Uptake Permease (KUP) Family 2.A.73 The Short Chain Fatty Acid Uptake (AtoE) Family 2.A.74 The 4 TMS Multidrug Endosomal Transporter (MET) Family 2.A.75 The L-Lysine Exporter (LysE) Family 2.A.76 The Resistance to Homoserine/Threonine (RhtB) Family 2.A.77 The Cadmium Resistance (CadD) Family 2.A.78 The Branched Chain Amino Acid Exporter (LIV-E) Family 2.A.79 The Threonine/Serine Exporter (ThrE) Family 2.A.80 The Tricarboxylate Transporter (TTT) Family 2.A.81 The Aspartate:Alanine Exchanger (AAEx) Family 2.A.82 The Organic Solute Transporter (OST) Family 2.A.83 The Na+-dependent Bicarbonate Transporter (SBT) Family 2.A.84 The Chloroplast Maltose Exporter (MEX) Family 2.A.85 The Aromatic Acid Exporter (ArAE) Family 2.A.86 The Autoinducer-2 Exporter (AI-2E) Family (Formerly the PerM Family, TC #9.B.22) 2.A.87 The Prokaryotic Riboflavin Transporter (P-RFT) Family 2.A.88 Vitamin Uptake Transporter (VUT or ECF) Family 2.A.89 The Vacuolar Iron Transporter (VIT) Family 2.A.90 Vitamin A Receptor/Transporter (STRA6) Family 2.A.91 Mitochondrial tRNA Import Complex (M-RIC) (Formerly 9.C.8) 2.A.92 The Choline Transporter-like (CTL) Family 2.A.94 The Phosphate Permease (Pho1) Family 2.A.95 The 6TMS Neutral Amino Acid Transporter (NAAT) Family 2.A.96 The Acetate Uptake Transporter (AceTr) Family 2.A.97 The Mitochondrial Inner Membrane K+/H+ and Ca2+/H+ Exchanger (LetM1) Family 2.A.98 The Putative Sulfate Exporter (PSE) Family 2.A.99 The 6TMS Ni2+ uptake transporter (HupE-UreJ) Family 2.A.100 The Ferroportin (Fpn) Family 2.A.101 The Malonate Uptake (MatC) Family (Formerly UIT1) 2.A.102 The 4-Toluene Sulfonate Uptake Permease (TSUP) Family 2.A.103 The Bacterial Murein Precursor Exporter (MPE) Family 2.A.104 The L-Alanine Exporter (AlaE) Family 2.A.105 The Mitochondrial Pyruvate Carrier (MPC) Family 2.A.106 The Ca2+:H+ Antiporter-2 (CaCA2) Family 2.A.107 The MntP Mn2+ Exporter (MntP) Family 2.A.108 The Iron/Lead Transporter (ILT) Family 2.A.109 The Tellurium Ion Resistance (TerC) Family 2.A.110 The Heme Transporter, heme-responsive gene protein (HRG) Family 2.A.111 The Na+/H+ Antiporter-E (NhaE) Family 2.A.112 The KX Blood-group Antigen (KXA) Family 2.A.113 The Nickel/cobalt Transporter (NicO) Family 2.A.114 The Putative Peptide Transporter Carbon Starvation CstA (CstA) Family 2.A.115 The Novobiocin Exporter (NbcE) Family 2.A.116 The Peptidoglycolipid Addressing Protein (GAP) Family 2.A.117 The Chlorhexadine Exporter (CHX) family 2.A.118 The Basic Amino Acid Antiporter (ArcD) Family 2.A.119 The Organo-Arsenical Exporter (ArsP) Family 2.A.120 The Putative Amino Acid Permease (PAAP) Family 2.A.121 The Sulfate Transporter (CysZ) Family 2.A.122 The LrgB/CidB holin-like auxiliary protein (LrgB/CidB) Family 2.A.123 The Sweet; PQ-loop; Saliva; MtN3 (Sweet) Family 2.A.124 The Lysine Exporter (LysO) Family 2.A.125 The Eukaryotic Riboflavin Transporter (E-RFT) Family 2.A.126 The Fatty Acid Exporter (FAX) Family 2.A.127 Enterobacterial Cardiolipin Transporter (CLT) Family
=== United States === 177Lu-DOTATATE (international nonproprietary name: lutetium (177Lu) oxodotreotide) was approved by the FDA in early 2018, for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Portugal has contributed to the popularity and globalisation of sport through internationally recognised athletes such as Cristiano Ronaldo, Ricardinho, Naide Gomes, and Carlos Lopes, as well as through the popularity of its three largest football clubs. Football is the most popular sport in Portugal. The Portugal men's national football team won the UEFA European Championship in 2016 and the UEFA Nations League in 2019 and 2025. Portugal is among the world's leading futsal countries, with its men's national team having won the FIFA Futsal World Cup in 2021, the UEFA Futsal Championship in 2018 and 2022, and the Futsal Finalissima in 2022. In athletics, the country has set several records and has earned more medals in this sport than in any other at both the Olympic and Paralympic Games. In traditional sport, Portugal is noted for its classical dressage as well as native sports such as jogo do pau and jogo da malha. Portugal has several established sporting centres across the country, including the Algarve and Lisbon, which are international golf destinations and have hosted motorsport events such as Formula One and Grand Prix motorcycle racing, as well as Nazaré and Peniche, which are known for surfing and annually host the TUDOR Nazaré Big Wave Challenge and the MEO Rip Curl Pro Portugal, respectively.
Sources: en.wikipedia.org
Some hemoglobinopathies seem to have given an evolutionary benefit, especially to heterozygotes, in areas where malaria is endemic. Having a mild form of alpha thalassemia has been demonstrated to protect against malaria and thus can be an advantage in malaria endemic areas, thus conferring a selective survival advantage on carriers (known as heterozygous advantage), and perpetuating the mutation. Alpha thalassemia genes have a high prevalence in populations originating in sub-Saharan Africa, Mediterranean, Middle East, and southeast and east Asia; all areas which historically have been malaria endemic. The prevalence of these genes has increased in previously non-endemic areas as a consequence of migration flows, slave-trade, and colonization. A number of mechanisms have been proposed to explain the increased chance of survival for the carrier of an abnormal hemoglobin trait.
The substrates of the enzyme are α-ketoisovaleric acid, coenzyme A (CoA), and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are isobutyryl-CoA, carbon dioxide, reduced NADH and a proton.
As clean energy from wind, solar or hydro storage replaces pollution from gas, oil and coal, EU law has standards for generation and distribution networks. First, in generation, the Renewable Energy Directive 2018 still enables biomass and biofuel to count toward "renewable" energy statistics based on the argument that trees or plants absorb greenhouse gases when they grow, even though biomass burning (usually in ex-coal plants) releases more greenhouse gases than coal, biomass transport is not clean, forests take decades to replenish, and smoke damages human health. Second, the EU does not yet have a feed-in tariff system, requiring energy grids and retailers to pay a fair price to households or businesses with solar or wind generation, however in PreussenElektra AG v Schleswag AG the Court of Justice held that member states could fix any price they chose, so that energy companies would have to reimburse producers for the energy they received. A company now owned by E.ON claimed the feed-in tariff was state aid under TFEU article 107, and should have to pass rules for exemption, as a way to hinder renewable energy funding. The Court rejected this, because although the policy might have 'negative repercussions' for big energy companies it 'cannot be regarded' as giving to small producers 'a particular advantage at the expense of the state'.
== Etiopathogenesis == Recent studies suggest that the pathogenesis of DM is driven by the pathogenic internalization of autoantibodies. Although these antibodies target intracellular proteins, evidence indicates that they can enter different cell types and disrupt the function of their target autoantigens causing inflammation and damage. For example, anti-Mi-2 autoantibodies bind PHD-containing proteins, including component of the NuRD complex, inducing derepression of multiple genes, and in anti-MDA5 dermatomyositis, autoantibodies activate MDA5 directly inducing the activation of type I interferon pathways. The type I interferon pathway is especially prominent in DM and has become a major therapeutic target. Clinical responses to JAK inhibitors, anti-IFNβ therapy, and agents targeting the interferon receptor support the importance of this pathway in disease activity. Conversely, a negative trial of complement inhibition in immune-mediated necrotizing myopathy has challenged earlier models in which complement-mediated muscle injury was considered central to that subtype. The characteristic pathological feature is perifascicular muscle involvement, often accompanied by vasculopathy. Plasma cells are found in close proximity to affected areas with high type I interferon expression and have been observed to externalize immunoglobulin heavy- and light-chain RNA into surrounding muscle cells, suggesting that this may be a potential mechanism for immunoglobulin entry into affected cell types shared across different forms of DM.
Some meteorologists prefer the hectopascal (hPa) for atmospheric air pressure, which is equivalent to the older unit millibar (mbar). Similar pressures are given in kilopascals (kPa) in most other fields, except aviation where the hecto- prefix is commonly used. The inch of mercury is still used in the United States. Oceanographers usually measure underwater pressure in decibars (dbar) because pressure in the ocean increases by approximately one decibar per metre depth. The standard atmosphere (atm) is an established constant. It is approximately equal to typical air pressure at Earth mean sea level and is defined as 101325 Pa (IUPAC recommends the value 100000 Pa, but prior to 1982 the value 101325 Pa (= 1 atm) was usually used). Because pressure is commonly measured by its ability to displace a column of liquid in a manometer, pressures are often expressed as a depth of a particular fluid (e.g., centimetres of water, millimetres of mercury or inches of mercury). The most common choices are mercury (Hg) and water; water is nontoxic and readily available, while mercury's high density allows a shorter column (and so a smaller manometer) to be used to measure a given pressure. The pressure exerted by a column of liquid of height h and density ρ is given by the hydrostatic pressure equation p = ρgh, where g is the gravitational acceleration. Fluid density and local gravity can vary from one reading to another depending on local factors, so the height of a fluid column does not define pressure precisely.
Sources: en.wikipedia.org
=== Domestic === Syria: Syria condemned the Israeli strikes on Syria and asserted their right to self-defense. The foreign ministry said that Israel's "flagrant assault, which forms part of a deliberate policy pursued by the Israeli entity to inflame tensions, spread chaos, and undermine security and stability in Syria, constitutes a blatant violation of the United Nations Charter and international humanitarian law". The head of security in Suwayda, Suleiman Abdul Baqi, declared "that some of the Druze in Israel who misled Hikmat al-Hijri into believing he would be granted a "state" have no influence in Washington" and "the American administration supports President Ahmed al-Sharaa and a unified Syrian state, and is against any separatist project or separatist groups, and does not support any Syrian component except through sending humanitarian aid, and supports the security and stability of Syria". Rojava/DAANES: The SDF condemned the violence in Suwayda, commenting on the civilian casualties in the conflict. The Kurdish women-led YPJ in particular expressed its readiness to "protect Druze women and civilians, [and to] shoulder all the responsibility placed upon us without hesitation". On 17 July 2025 the Social Affairs and Labor Authority of the DAANES dispatched humanitarian aid to Suwayda Governorate. Suwayda Military Council: An official statement was issued declaring a state of maximum alert. The council announced that all combat units under its command had been placed on maximum alert, prepared for immediate intervention if deemed necessary to protect civilians.
=== Preventing and treating infection === To lower the bacterial count in wounds, therapists may use topical antibiotics, which kill bacteria and can also help by keeping the wound environment moist, which is important for speeding the healing of chronic wounds. Some researchers have experimented with the use of tea tree oil, an antibacterial agent which also has anti-inflammatory effects. Disinfectants are contraindicated because they damage tissues and delay wound contraction. Further, they are rendered ineffective by organic matter in wounds like blood and exudate and are thus not useful in open wounds. A greater amount of exudate and necrotic tissue in a wound increases likelihood of infection by serving as a medium for bacterial growth away from the host's defenses. Since bacteria thrive on dead tissue, wounds are often surgically debrided to remove the devitalized tissue. Debridement and drainage of wound fluid are an especially important part of the treatment for diabetic ulcers, which may create the need for amputation if infection gets out of control. Mechanical removal of bacteria and devitalized tissue is also the idea behind wound irrigation, which is accomplished using pulsed lavage. Removing necrotic or devitalized tissue is also the aim of maggot therapy, the intentional introduction by a health care practitioner of live, disinfected maggots into non-healing wounds. Maggots dissolve only necrotic, infected tissue; disinfect the wound by killing bacteria; and stimulate wound healing.
Cannabis has been one of the most used psychoactive drugs in the world since the late 20th century, following only tobacco and alcohol in popularity. According to Vera Rubin, the use of cannabis has been encompassed by two major cultural complexes over time: a continuous, traditional folk stream, and a more circumscribed, contemporary configuration. The former involves both sacred and secular use, and is usually based on small-scale cultivation: the use of the plant for cordage, clothing, medicine, food, and a "general use as an euphoriant and symbol of fellowship." The second stream of expansion of cannabis use encompasses "the use of hemp for commercial manufacturers utilizing large-scale cultivation primarily as a fiber for mercantile purposes"; but it is also linked to the search for psychedelic experiences (which can be traced back to the formation of the Parisian Club des Hashischins).
== Diagnosis == Diagnosis typically occurs in the first few years of life and should be confirmed with a review of symptoms as well as genetic testing with targeted panels that include the ALMS1 gene as well as other ciliopathies, retinal diseases, cardiomyopathy, and obesity. Typically, the first symptoms to be observed are nystagmus, photophobia, impaired vision, and/or infantile cardiomyopathy within the first two years of life. Obesity and/or sensorineural hearing loss are often next and should be followed by genetic/molecular testing to try and identify two pathogenic variants of ALMS1 to confirm or deny the presence of the disease. However, the rarity of the disease, variability of symptoms, and lack of experts can make diagnosis very difficult. Additionally, since it can be difficult to identify both biallelic pathogenic variants in the ALMS1 gene, there is existing diagnostic criteria as shown below.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.